Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00324038
Recruitment Status : Completed
First Posted : May 10, 2006
Results First Posted : March 30, 2010
Last Update Posted : June 14, 2011
Information provided by:
Napp Pharmaceuticals Limited

Brief Summary:
The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: Buprenorphine Drug: Codeine paracetamol Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 219 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Randomised, Multicentre Study to Compare Buprenorphine Transdermal Delivery System (BTDS) With Standard Treatment in Elderly Subjects With OA of the Hip and/or Knee
Study Start Date : March 2006
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: buprenorphine transdermal system
Buprenorphine transdermal 7 day analgesic patch
Drug: Buprenorphine
buprenorphine transdermal system 5, 10 and 20 mg
Other Name: BuTrans/Norspan

Active Comparator: codeine paracetamol tablets
codeine paracetamol combination tablets
Drug: Codeine paracetamol
combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
Other Name: Co-codamol tablets

Primary Outcome Measures :
  1. Average Daily Pain Scores - BS11 Pain Scores. [ Time Frame: every day over a 12 week study duration. ]
    The primary efficacy variable was the average daily pain score recorded on a Box Scale-11 pain scale in the evening. 0 = no pain and 10 = most pain imaginable. Subjects ticked the box from 0 - 10 which best describes their level of pain.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Either sex aged 65 or above
  • Diagnosis of OA of the hip and/or knee
  • Severe pain requiring step two medication
  • Taking maximum dose of paracetamol

Exclusion Criteria:

  • Painful disease of the joints other than OA
  • Contraindication to buprenorphine, other opioids, patch adhesives or nonsteroidal anti-inflammatory agents (NSAIDS)
  • Subjects taking cyclooxygenase (COX) II selective inhibitors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00324038

Layout table for location information
United Kingdom
Napp Pharmaceuticals Ltd
Cambridge, United Kingdom, CB4 0GW
Sponsors and Collaborators
Napp Pharmaceuticals Limited
Layout table for investigator information
Principal Investigator: Prof Philip Conaghan
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr J Paul Schofield, Napp Pharmaceuticals Ltd Identifier: NCT00324038    
Other Study ID Numbers: 2005-004279-39
First Posted: May 10, 2006    Key Record Dates
Results First Posted: March 30, 2010
Last Update Posted: June 14, 2011
Last Verified: June 2011
Keywords provided by Napp Pharmaceuticals Limited:
OA of the hips and/or knees
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Analgesics, Opioid
Central Nervous System Depressants
Narcotic Antagonists
Antitussive Agents
Respiratory System Agents